Polpharma Biologics and Sandoz recently celebrated a milestone achievement by gaining the first endorsement for their partnered natalizumab biosimilar, in the form of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?